What is Leerink Partnrs’ Estimate for ENTA FY2027 Earnings?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Stock analysts at Leerink Partnrs upped their FY2027 earnings per share (EPS) estimates for Enanta Pharmaceuticals in a research report issued on Monday, September 29th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will earn ($1.42) per share for the year, up from their previous forecast of ($1.44). The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.65) per share. Leerink Partnrs also issued estimates for Enanta Pharmaceuticals’ FY2028 earnings at ($1.15) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.The company had revenue of $18.31 million for the quarter, compared to analyst estimates of $16.21 million.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright started coverage on shares of Enanta Pharmaceuticals in a research note on Monday, July 28th. They issued a “buy” rating and a $20.00 price target on the stock. Westpark Capital increased their price objective on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday. Evercore ISI decreased their target price on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a research note on Monday, September 15th. JMP Securities upped their price target on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 12th. Finally, Wall Street Zen raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 22nd. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $20.83.

Enanta Pharmaceuticals Stock Down 2.6%

Enanta Pharmaceuticals stock opened at $10.33 on Thursday. Enanta Pharmaceuticals has a 12-month low of $4.09 and a 12-month high of $15.34. The business’s 50-day moving average price is $8.31 and its two-hundred day moving average price is $6.96. The stock has a market cap of $220.86 million, a PE ratio of -2.39 and a beta of 0.89.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC boosted its stake in shares of Enanta Pharmaceuticals by 34.1% in the 4th quarter. Jane Street Group LLC now owns 31,072 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 7,896 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Enanta Pharmaceuticals in the fourth quarter valued at $66,000. Public Employees Retirement System of Ohio boosted its position in Enanta Pharmaceuticals by 117.7% during the fourth quarter. Public Employees Retirement System of Ohio now owns 15,726 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 8,501 shares during the last quarter. Wellington Management Group LLP boosted its position in Enanta Pharmaceuticals by 47.6% during the fourth quarter. Wellington Management Group LLP now owns 51,298 shares of the biotechnology company’s stock valued at $295,000 after acquiring an additional 16,547 shares during the last quarter. Finally, GAMMA Investing LLC bought a new stake in Enanta Pharmaceuticals during the first quarter valued at $40,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.